TaiGen Biotech Eyes Pneumonia Antibiotic On China's Market By Year End

TaiGen Biotechnology said China trials of its Taigexyn (nemonoxacin) pneumonia antibiotic are running smoothly and it estimates a $1.6 million market value in China by the end of the year.